Summary

Overview
Global Antibody-mediated Rejection market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Antibody-mediated rejection (AMR) refers to all allograft rejections caused by antibodies that target donor-specific HLA molecules, blood group antigen (ABO)-isoagglutinins, or endothelial cell antigens. AMR can result in damage to the transplanted organ, such as a kidney, and can cause various symptoms depending on the organ involved, such as difficulty breathing, cough, and fever.
One third of organ transplants are failed due to transplant rejection. Although acute transplant rejection responds fairly reasonably to steroids, chronic rejection (which is predominantly mediated by antibodies) has no adequate therapy.
Market Dynamics: Drivers & Restraints
Increasing Organ Transplants Conducted
The global market growth for antibody-mediated rejection is expected to increase due to the rise in the number of organ transplants conducted. For example, according to preliminary data from the United Network for Organ Sharing (UNOS), over 42,887 organ transplants were conducted in the United States in 2022, which is an increase of 3.7% over 2021 and a new annual record. Additionally, the Global Observatory on Donation and Transplantation reported that over 144,302 organs were transplanted in 2021, indicating an 11.3% increase over 2020, with 16 transplants per hour in 2021. However, it's worth noting that there were only 38,156 actual deceased organ donors in 2021.
Additionally, the increase in awareness, technological advancements, and increasing research activities with investments and funding are among the additional factors boosting the global market growth during the forecast period.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the new drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
Segment Analysis
The global antibody-mediated rejection market is segmented based on treatment, route of administration, distribution channel and region.
Biologics Treatment is Expected to Dominate Market
The increasing research activities for developing biologics treatments for antibody-mediated rejection are expected to boost the segment's growth in the global market. For example, HI-Bio's Felzartamab is currently in development for the treatment of late antibody-mediated renal allograft rejection, IgA nephropathy (IgAN), membranous nephropathy (anti-PLA2R antibody-positive membranous nephropathy), and refractory/relapsed multiple myeloma.
The company found that the decline in autoantibody levels occurred regardless of initial aPLA2R levels. Patients in the trial also reported decreases in proteinuria, a protein in the urine that, in high levels, can be indicative of poor kidney function. Furthermore, according to clinicaltrials.gov, there are currently two phase 2 and two phase 3 clinical trials recruiting, while two phase 2 and one phase 3 trials are currently active assessing the effectiveness and safety of monoclonal antibody nominees for antibody-mediated rejections.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increasing research activities to reduce transplant rejection in North America are expected to boost the regional market growth dominating the global market during the forecast period. For instance, Northwestern University scientists have designed the first electronic device for continually observing the health of transplanted organs in real time, positioned directly on a transplanted kidney, the ultrathin, soft implant can notice temperature anomalies associated with inflammation and other body reactions that occur with transplant rejection.
Moreover, seeking to enhance organ transplant survival rates, internationally recognized investigators in immunology and bioengineering at the Icahn School of Medicine at Mount Sinai have obtained $15.1 million from the National Institute of Allergy and Infectious Diseases (NIAID) to conduct a novel, five-year multi-center investigation schedule that intends study trained immunity the innate immune system’s capability to recognize infections and other insults as a mark for averting organ transplant rejection.
COVID-19 Impact Analysis
Several studies indicated that postrenal transplant patients have an elevated danger of intricacies with COVID-19 infection owing to their immunocompromised status and corresponding comorbidities. These caused a reduction in the treatment demand also owing to the restrictions posed by the pandemic many transplant surgeries were either postponed or canceled which also caused a reduction in treatment demand for antibody-mediated rejection negatively impacting the global market during the forecast period.
Market Segmentation
By Treatment
• Corticosteroids
• Biologics
• Immunosuppressants
• Plasmapheresis
• Others
By Route of Administration
• Injectable
• Oral
• Other
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In August 10, 2023, the PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been granted a five-year award to provide a Transplantation Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in the United States.
• In February 2021, Horizon Therapeutics acquired the AstraZeneca spinout Viela Bio for $3 billion. The confiscation is expected to provide Horizon a grip of clinical-phase autoimmune and inflammatory disorder drug nominees, R&D capacities and an authorized monoclonal antibody.
Competitive Landscape
The major global players in the market include CSL Behring, Hansa Biopharma, Novartis AG, Talaris Therapeutics, Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd, Ltd. and Biogen among others.
Why Purchase the Report?
• To visualize the global antibody-mediated rejection market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of antibody-mediated rejection market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global antibody-mediated rejection market report would provide approximately 61 tables, 59 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Organ Transplants Conducted
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Corticosteroids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Biologics
7.4. Immunosuppressants
7.5. Plasmapheresis
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Injectable*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
8.4. Other
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. CSL Behring*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Hansa Biopharma
12.3. Novartis AG
12.4. Talaris Therapeutics
12.5. Amgen Inc.
12.6. Bristol-Myers Squibb
12.7. Eli Lilly and Comapny, Inc.
12.8. Sanofi S.A.
12.9. Teva Pharmaceuticals Industries Ltd, Ltd.
12.10. Biogen
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us